Off-label use of rituximab for systemic lupus erythematosus in Europe.

Ryden-Aulin, Monica; Boumpas, Dimitrios; Bultink, Irene; Rubio, Jose; Caminal-Montero, Luis; Castro, Antoni; Colodro Ruiz, Agustin; Doria, Andrea; Domer, Thomas; Gonzalez-Echavarri, Cristina; Gremese, Elisa; Houssiau, Frederic; Huizinga, Tom; Inana, Murat; Isenberg, David; Luliano, Annamaria; Jacobsen, Soren; Jimenez-Alonso, Juan; Kovacs, Laszlo; Mariette, Xavier; Mosca, Marta; Nived, Ola; Oristrell, Joaquim; Ramos-Casals, Manuel; Rascon, Javier; Ruiz-Irastorza, Guillermo; Saez-Comet, Luis; Salvador Cervello, Gonzalo; Ruiz-Irastorza, Guillermo; Saez-Comet, Luis; Cervello, Gonzalo; Sebastiani, Gian; Squatrito, Danilo; Szucs, Gabriella; Voskuyl, Alexandre; van Vollenhoven, Ronald

doi:10.1136/lupus-2016-000163

Off-label use of rituximab for systemic lupus erythematosus in Europe.

Atıf İçin Kopyala

Ryden-Aulin M., Boumpas D., Bultink I., Rubio J. L. C., Caminal-Montero L., Castro A., ...Daha Fazla

Lupus science & medicine, cilt.3, sa.1, 2016 (Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 3 Sayı: 1
Basım Tarihi: 2016
Doi Numarası: 10.1136/lupus-2016-000163
Dergi Adı: Lupus science & medicine
Derginin Tarandığı İndeksler: Scopus
İstanbul Üniversitesi Adresli: Evet

Özet

Objectives: Rituximab (RTX) is a biological treatment used off-label in patients with systemic lupus erythematosus (SLE). This survey aimed to investigate the off-label use of RTX in Europe and compare the characteristics of patients receiving RTX with those receiving conventional therapy.